The question of whether or not there is a polymorphism in or near DRD2 which is associated with receptor density remains unanswered. Both clinical and animal data demonstrate that D 2 dopamine receptor density is highly variable among individuals; differences of more than 100% are not uncommon. Among inbred mouse strains and F 2 intercrosses produced from these strains, it appears that most of the genetic variation in receptor expression is not associated with polymorphisms in or near Drd2.
Two reports in this issue of Molecular Psychiatry 1, 2 refocus our attention on an issue that has been controversial for almost a decade, namely, 'Is there a polymorphism in or near DRD2 which is associated with the regulation of receptor density?' Laruelle et al 1 examined the effects of both the Taq1 'A' and 'B' polymorphisms on D2 receptor-binding potential (B max /K d ) using SPECT technology with the ligand 123I-IBZM in 70 subjects; a previous postmortem study suggested that the A1 allele was associated with a mutation that decreases receptor expression. 3 Laruelle et al 1 found that the A1 carriers (subjects homozygous or heterozygous for the allele) had the same binding potential as the non-carriers. Similarly, they found that the polymorphisms of the Taq1 'B' system, which is in strong linkage disequilibrium with the 'A' system, had no effect on binding potential. Pohjalainen et al 2 examined the relationship between the Taq1 'A' system polymorphisms and binding potential using PET and 11 C-raclopride in 54 Finnish normal volunteers. A significant decrease (15-20%) in binding potential was found for the A1/A2 heterozygotes as compared to A2/A2 homozygotes; the effect was sustained after the data were age or gender adjusted. Can the different results between the two studies be explained? Both groups used a substituted benzamide as the receptor ligand, reported the data as binding potential and the A1 allele frequency was similar in the two study populations. There was however, an important experimental difference, namely the reduced coefficient of variation in the PET study. Thus, the Pohjalainen et al 2 study had significantly greater power to detect a small difference. This point becomes important when one considers that the study population used by Laruelle et al 1 was composed of 47 normal controls and 23 schizophrenics. Among the normal control A1 carriers there was a trend to a lower binding potential but the sample size had insufficient power to detect the difference, if real. The schizophrenics actually showed a trend in the opposite direction, although these data may be confounded by prior neuroleptic exposure. Overall, after reading these two reports, one is left in the rather unsatisfying position of still being unsure as to whether or not the A1 allele is associated with lower binding potential.
To understand the importance of this issue, it is necessary to put the studies in the proper historical perspective. Both studies trace their origin to the observation of Blum et al 4 that there was an association between the A1 allele and alcoholism. Some [5] [6] [7] [8] [9] [10] [11] [12] but not all [13] [14] [15] [16] [17] subsequent studies have confirmed this association for alcoholism and stimulant abuse. Population stratification is a potentially important confound in studies of the A1 allele. Barr and Kidd 18 examined 381 people from 16 different populations and found that the frequency of the A1 allele varies widely from 0.09 to 0.75. These significant differences make it imperative that one should control for the ethnic origin of subjects when performing an association study with the A1 allele; lack of concern for this issue appeared to be a problem in some of the earlier studies. A recent study by Chen et al 19 illustrates the importance of this point. These authors examined the relationships among Taq1 and NcoI D2 receptor polymorphisms and alcoholism in four aboriginal groups and the Han (Chinese) in Taiwan. Haplotype analysis revealed a significant association of the A1N1 haplotype and alcoholism only in the Ami (one of the aboriginal populations) and the Han. The authors conclude that the absence of the association between the polymorphisms in DRD2 and alcoholism in three of the aboriginal populations suggests either a higher rate of phenocopies among aboriginal alcoholics or genetic heterogeneity in the susceptibility to alcoholism.
The emphasis on the relationships between DRD2 and alcohol/substance abuse builds from the proposed role of the D 2 dopamine system in reward mechanisms 20 and from the in vivo observations that chronic alcoholics, cocaine and heroin abusers have a lower D 2 receptor-binding potential which persists (for up to months) after drug withdrawal. [21] [22] [23] [24] [25] The receptor data come largely from a single group of investigators. [22] [23] [24] It is important to note that in these studies the alcoholics and cocaine addicts were a highly selected group. For example, the alcoholics needed to use Ͼ3 g of ethanol kg −1 daily but needed to be otherwise medically stable, not abusing other substances and with a family history positive for alcoholism. Approximately one out of 20 alcoholics screened met these study criteria. The selection of the cocaine addicts was similarly stringent; importantly, from the genetic perspective, all of these subjects were also family history positive for substance or alcohol abuse. For the cocaine addicts the reduction of D 2 receptor-binding potential was detected in two separate studies, using two different receptor ligands. 23, 24 In none of the studies was it possible to determine if the binding potential returned to normal. Thus, there are no data which support either a 'state' or 'trait' mechanism for the lower binding potential.
Interest in D 2 receptor genetics also builds from the putative role of the D 2 receptor system in a wide variety of neuropsychiatric disorders. For example, some data suggest that schizophrenics have a higher receptor density than controls and this difference is not the result of neuroleptic exposure. 26 However, most [27] [28] [29] but not all studies 30 have been unable to detect a significant association between polymorphisms in DRD2 and schizophrenia. Negative results have also been obtained for affective disorders, 31, 32 obsessive compulsive disorder 33 and Tourettes' syndrome; 34 in contrast, a positive association has been reported for schizoid/avoidant behaviors. 35 These largely negative results should not be unexpected; as will be shown below, most of the variance in receptor expression is probably not associated with polymorphisms in DRD2.
There is remarkable variation among individuals in the apparent availability of D 2 receptors. The coefficients of variation in the studies of Laruelle et al 1 
and Pohjalainen et al
2 range from 30 to 50%. Thus, those individuals more than and less than one standard deviation from the mean will differ from each other by more than 85% in receptor-binding potential. Some of the difference among individuals may be associated with differences in synaptic dopamine concentrations. Both raclopride and IBZM have a 'relatively' low affinity for the D 2 receptor and thus, significant receptor competition is expected between either of these ligands and endogenous dopamine. If this competition contributes significantly to the variation in binding potential, most of the variation in binding potential should come from changes in K D and not B max . Pohjalainen et al 2 addressed this issue by administering raclopride at both low and high specific activity to each subject and calculating individual K D values. No significant variation in K D was observed. These data are consistent with the animal data which show that K D does not vary among inbred strains of mice and rats. 36 Further, naturally occurring variants in the human receptor eg the Ser 311 → Cys variant, do not appear to be associated with differences in receptor-binding affinity. 37 Thus, it appears that the individual differences in binding potential are due either to environmental effects or genetic effects on receptor density. The strongest evidence that some of this receptor variance is related to genetic factors comes from animal studies. A useful starting point for reviewing this literature is the work of Helmeste and Seeman 38 and Ciarenello and Boehme. 39 These authors used membrane-binding assays to examine striatal D 2 receptor density among inbred mouse strains; a difference among inbred strains is presumed to be of genetic origin. Five inbred strains were common to both studies; importantly the relative order of receptor density for the three most commonly used strains in biomedical research was similar with the BALB/cJ Ͼ C57BL/6J (C57) Ͼ DBA/2J (DBA). Receptor density in the BALB/cJ strain was 60-80% higher than in the DBA strain. Subsequent studies [40] [41] [42] [43] [44] have confirmed that there is a marked difference in receptor density among inbred mouse strains. However, it is important to note that the relative difference among strains depends on the region examined. For example, the C57 strain has a higher receptor density than the DBA strain in the striatum 43, 44 but a lower receptor density in the substantia nigra and ventral tegmental area; 44 the latter difference in part is related to a higher number of midbrain dopamine neurons in the DBA strain. 45 Differences in receptor density have also been found among inbred rat strains in some [46] [47] [48] but not all studies. 49 Luedtke et al 49 also examined the differences among five inbred rat strains in the ratio of D2 receptor mRNA for the long and short splice variants (the long and short splice variants differ by a 29-amino acid insert in the third cytoplasmic loop). No difference in the long and short isoforms of the mRNA was noted among the strains. Similarly, we have found no difference in the ratio of the splice variants between the C57 and DBA inbred mouse strains; further the amino acid sequences in both strains are identical (unpublished observations).
An important confound to detecting differences in D 2 receptor density is the age at which the measurements are made. For example, Lephohon-Greenwood and Cinader 50 examined D 2 receptor binding among females of five inbred strains (C57BL/6, SJL, A, DBA/1 and C3H/He). At 7-15 weeks of age (the time of measurement in most laboratory experiments), the order of receptor binding was C57 Ͻ SJL Ͻ A = DBA/1 = C3H and the range of receptor density values was nearly 100%. Interestingly, these authors found that there are marked age-related declines in receptor density for all strains except the C57, such that by 31-45 weeks of age there was no difference among strains. No further difference among strains was seen up to 120 weeks (even though there were age-related losses in receptor density). In a subsequent study, 51 these authors argued that in animals with a relatively low 'youthful' receptor density, aging had modest effects. On the other hand, in animals with a high 'youthful' receptor density eg the MRL/Mp −2+ strain, aging causes a marked receptor loss. These authors termed the phenomenon of receptor loss being greatest in the strains with the highest receptor density 'economic correction'. The obvious question arises as to whether or not such economic correction occurs in humans. We must consider the possibility that disorders with a young adult onset eg schizophrenia, may be associated with significant abnormalities in receptor density; however, at the time of ascertainment (usually years later) economic correction will have muted differences between patients and normal controls.
In addition to the work on receptor density, there is a large body of data which documents marked differences among inbred strains in their behavioral responses to the administration of D 2 receptor agonists, antagonists and related compounds (reviewed in 52 ). ). 44, 52, 53 This difference in response is not the result of differences in drug uptake and/or metabolism. 44 Further, drugs with a more selective pharmacological profile than haloperidol eg raclopride, a specific D 2 /D 3 receptor antagonist, show the same range of response differences among the inbred strains. Interestingly, there is essentially no difference among inbred strains in catalepsy induced by the D 1 antagonist, SCH 23390. 44 In addition to the work on inbred strains, we have also selectively bred mice for increased and decreased responsiveness to haloperidol-induced catalepsy. 54, 55 Beginning with a heterogeneous stock formed by crossing eight inbred strains, selective breeding leads to a rapid divergence of the responsive and non-responsive lines such that by the fifth selected generation, the lines differ in their ED 50 values by approximately 10-fold. These studies on the inbred strains and selected lines are particularly pertinent to the topic of this report since we have repeatedly made the paradoxical observation that the non-responsive animals have the highest D 2 receptor density. 54, 56, 57 This point has also been confirmed in the phenotypic extremes (for the catalepsy response) of two unique F 2 intercross populations-one formed from the C57 and DBA strains and another formed from the BALB/c and LP strains. 53, 58 Thus, we conclude that some of the genes which regulate the catalepsy response also regulate D 2 receptor expression.
What are these genes? Our first attempt to find 'catalepsy related' genes was a two-step quantitative trait loci (QTL) analysis. 53 In step one, provisional QTLs were identified using the BXD recombinant inbred (RI) strains. This RI series which contains 26 strains was formed by Taylor and colleagues over 20 years ago beginning with the C57BL/6 and DBA/2 inbred strains and was originally intended to find single gene effects. The influence of a single major gene was inferred whenever a bimodal distribution was observed among the strain means, with one of the progenitor strains in each mode. The expected ratio of the two modes is 1:1 because all animals are homozygous. However, for behavioral and neurochemical phenotypes, a bimodal distribution is rarely observed; rather most phenotypes (including catalepsy) show a unimodal distribution which is consistent with the involvement of multiple genes. The chromosomal location of these genes is estimated by QTL analysis. The strain means (ED 50 values for haloperidol-induced catalepsy) were correlated with the strain distribution patterns of 1300 marker loci, which are polymorphic between the progenitor strains and whose chromosomal location is known. The significance of this correlation is the same as the regression of phenotype on gene dosage for a particular locus. 59 Six provisional or candidate QTLs were identified in this step at P Ͻ 0.01. The second step of the analysis focused on determining which of these QTLs were real and which resulted from chance correlation because of multiple comparisons. To accomplish this goal, 150 B6D2 F 2 intercross animals were phenotyped for the catalepsy response and then genotyped using microsatellite markers found in the candidate QTL intervals. Two of the QTLs were confirmed at P Ͻ 0.01 or better. One of the confirmed QTLs was near the b or tyrosinase-related protein (Tyrp1) locus on chromosome 4; the homologous locus in man is found at 9p23. The other confirmed QTL appeared to be either near or part of the Drd2 locus on chromosome 9. One hundred of the intercross animals were also phenotyped for D 2 receptor density. Focusing on the data from the core of the nucleus accumbens, the range of difference in receptor binding was more than 200%; further, it was observed that there was a significant relationship between genotype for D9Mit21 which is closely linked to Drd2, and receptor binding. Binding in the heterozygote and the D2D2 homozygote was significantly higher (approximately 20%) than in the B6B6 homozygote. Analogous experiments were conducted for microsatellite markers near the b locus; no association was detected between receptor phenotype and genotype. Overall, these data appeared to provide murine support for the hypothesis that a polymorphism in the D 2 receptor gene affects receptor density (the Taq 1 hypothesis). However, the data also strongly argued that most of the genetic variance in receptor density is associated with other genes.
Recent work in the laboratory now suggests that the QTL (for catalepsy) on chromosome 9 is probably somewhat distal to Drd2. It is important to note that the QTLs described above have 95% confidence intervals of 20-30 cM. To both reduce the confidence intervals and to search for additional QTLs with effect sizes smaller than those that could be detected in the BXD analysis, we have phenotyped 1500 B6D2 F 2 intercross progeny and begun a genome-wide scan focusing on the phenotypic extremes. The QTL near the b locus is again confirmed but only for the female progeny; gender-specific QTLs may prove to be an important confound to mapping studies. The QTL on chromosome 9 was first confirmed simply on the basis of dilute coat color-160% higher in the non-responsive extreme. Microsatellite-based genotypic analysis has revealed that the chromosome 9 QTL is indeed centered on the d locus, which is approximately 15 cM distal to the Drd2 locus. The estimated LOD score for this QTL is 7. A likely candidate gene near the d locus is Htr1b. High densities of 5-HT 1B receptors are found on nerve terminals in the basal ganglia output nuclei eg the subthalamic nucleus and substantia nigra zona reticulata, 60 where their function is to regulate transmitter, largely GABA release. The question of whether or not there is a polymorphism between the C57 and DBA strains in Htr1b and whether or not this polymorphism affects catalepsy and/or D 2 receptor density remains to be determined. Further, these data do not exclude the possibility that a functionally important polymorphism exists at Drd2. The data only suggest that if two QTLs are present, the QTL near or in Htr1b has a larger effect on the phenotypes of interest. The strategy we are using to untangle this issue is to develop congenic strains in which segments of DNA from the DBA strain either containing Drd2 and/or Htr1b are introgressed into the recipient C57 strain. This strategy will allow us to examine the effects of the naturally occurring polymorphisms. Once a functional effect is established, interval-specific congenics can be formed to precisely locate the polymorphism. 61 Importantly, the QTL near or a part of Htr1b has been confirmed in a completely independent F 2 cross formed from the BALB/cJ and LP/J inbred strains. 58 Of course these data do not demonstrate that the same gene or genes are involved in both crosses. However, these data do suggest that this region of mouse chromosome 9 is generally important to the regulation of the catalepsy response (and probably to the regulation of D 2 receptor density). Further, these data suggest that it would be reasonable to examine in human samples, the relationships between polymorphisms in HTR1B and D 2 receptor density (or binding potential). Interestingly, HTR1B is found at 6q13, in a region of chromosome 6 which has also been implicated in schizophrenia. 62 Overall, we have concluded that murine D 2 receptor density appears to be a complex phenotype, under the control of multiple genes, each of which is likely to have only a moderate effect size. Further, although there may be a polymorphism in Drd2 that is associated with the regulation of receptor density, other genes control most of the variance. The search for these genes is hindered by a lack of understanding of the molecular mechanisms responsible for the variance in receptor expression. It would be natural to point to differences in the rate of transcription as the source of the variance in receptor expression. Although it is clear that the receptor can be up and down regulated through pharmacological manipulation, little is known about the actual molecular mechanisms. The promoter for DRD2 has not been extensively characterized. 63, 64 Furthermore, mismatches between mRNA levels and receptor density are common for the D 2 receptor (as they are for many other receptors). For example, we have been unable to show that there is a relationship between mRNA levels (as determined by quantitative nuclease protection assay) and the differences in receptor density introduced by selective breeding for the catalepsy response (see above). 56, 57 Similarly, several investigators have been unable to show a relationship between the increase in receptor density which occurs after chronic haloperidol administration and mRNA levels. 65, 66 Mismatches have also been found for the age-related loss of receptor density. 67 There is a reasonably good association between mRNA levels and the striatal receptor gradients; 57 however, these gradients appear to be genetically invariant. 44 Among the selected lines we concluded that the receptor density differences were associated with post-translational effects on receptor production; receptor degradation appeared unchanged. The important point here is that receptor density can be affected at numerous points in the 'receptor life cycle' and no single main point of regulation has emerged.
The general argument which underlies the research of Laruelle et al 1 and Pohjalainen et al 2 as well as the research conducted in our laboratory is that there are genes which regulate the function of the basal ganglia and in turn regulate a wide variety of behaviors. The complexity of this statement cannot be underestimated. In addition to the general problem of detecting multiple genes each with small effects on the phenotypes of interest, one must deal with the enormous plasticity of the basal ganglia. The observation that most of the dopamine neurons can be lost before signs of Parkinsonism appear are well known to most investigators. It is also remarkable that 'knockout' mice have been formed for all the dopamine receptors, including D 2 , and for the dopamine transporter. While these mice are clearly not 'normal', the fact that they can survive is a testament to the fact that the basal ganglia can make enormous accommodations to insure the development of necessary functions. This point is underscored by the wide natural variation in D 2 receptor density among normal controls and the apparent lack of associated pathology. RJ Hitzemann, PhD Department of Psychiatry, SUNY at Stony Brook Stony Brook, NY 11794-8101, USA
